Enoxacin

Enoxacin
Clinical data
AHFS/Drugs.com	Monograph
MedlinePlus	a601013
Routes of; administration	Oral
ATC code	J01MA04 (WHO) ;
Identifiers
	IUPAC name 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid;
CAS Number	74011-58-8 ;
PubChem CID	3229;
DrugBank	DB00467 ;
ChemSpider	3116 ;
UNII	325OGW249P;
KEGG	D00310 ;
ChEBI	CHEBI:157175 ;
ChEMBL	ChEMBL826 ;
CompTox Dashboard (EPA)	DTXSID5022984 ;
Chemical and physical data
Formula	C15H17FN4O3
Molar mass	320.324 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	220 to 224 °C (428 to 435 °F)
	SMILES Fc1c(nc2c(c1)C(=O)C(\C(=O)O)=C/N2CC)N3CCNCC3;
	InChI InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23) ; Key:IDYZIJYBMGIQMJ-UHFFFAOYSA-N ;
	(verify)

Enoxacin is an oral broad-spectrum fluoroquinolone antibacterial agent used in the treatment of urinary tract infections and gonorrhea. Insomnia is a common adverse effect. It is no longer available in the United States.

Enoxacin may have cancer inhibiting effect.